Metabolic syndrome and inflammatory biomarkers: a community-based cross-sectional study at the Framingham Heart Study

Diabetology & Metabolic Syndrome

Emelia J Benjamin¹  Caroline S Fox⁶  James B Meigs²  Joao D Fontes⁵  John F Keaney⁴  Ramachandran S Vasan⁷  Martin G Larson³  Dhayana Dallmeier⁶ 

[1]Epidemiology Department, Boston University School of Public Health, Boston, USA

[2]Department of Medicine, Harvard Medical School, Boston, USA

[3]Department of Mathematics and Statistics, Boston University, Boston, USA

[4]Cardiovascular Medicine, University of Massachusetts Medical School, Worcester, USA

[5]Cardiology, Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, USA

[6]National Heart, Lung, and Blood Institute’s and Boston University’s Framingham Heart Study, Framingham, USA

[7]Preventive Medicine Divisions, Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, USA

关键词: Insulin resistance;    Body mass index;    Inflammatory biomarkers;    Metabolic syndrome;   

Others  :  814958
DOI  :  10.1186/1758-5996-4-28

 received in 2011-12-21, accepted in 2012-05-24,  发布年份 2012

【 摘 要 】

Background

Prior studies reported conflicting findings on the association between metabolic syndrome and inflammatory biomarkers. We tested the cross-sectional associations between metabolic syndrome and nine inflammatory markers.

Methods

We measured C-reactive protein, CD40 ligand, interleukin-6, intercellular adhesion molecule-1, monocyte chemoattractant protein-1, osteoprotegerin, P-selectin, tumor necrosis factor-alpha, and tumor necrosis factor receptor-2 in 2570 Framingham Offspring Study participants free of diabetes and cardiovascular disease at examination 7. Metabolic syndrome was defined by National Cholesterol Education Program criteria. We performed multivariable linear regressions for each biomarker with metabolic syndrome as the exposure adjusting for age, sex, smoking, aspirin use, and hormone replacement. We subsequently added to the models components of the metabolic syndrome as continuous traits plus lipid lowering and hypertension treatments. We considered P < 0.05 as statistically significant.

Results

Metabolic syndrome was present in 984 (38%) participants and was statistically significantly associated with each biomarker (all P < 0.02) except osteoprotegerin. After adjusting for its component variables, the metabolic syndrome was associated only with P-selectin (1.06 fold higher in metabolic syndrome, 95% CI 1.02, 1.10, p = 0.005).

Conclusions

Metabolic syndrome was associated with multiple inflammatory biomarkers. However, adjusting for each of its components eliminated the association with most inflammatory markers, except P-selectin. Our results suggest that the relation between metabolic syndrome and inflammation is largely accounted for by its components.

【 授权许可】

   
2012 Dallmeier et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Hotamisligil GS: Inflammation and metabolic disorders. Nature 2006, 444(7121):860-867.
• [2]Pischon T, Hu FB, Rexrode KM, Girman CJ, Manson JE, Rimm EB: Inflammation, the metabolic syndrome, and risk of coronary heart disease in women and men. Atherosclerosis 2008, 197(1):392-399.
• [3]Haffner SM: The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol 2006, 97(2):11-13.
• [4]Langenberg C, Bergstrom J, Scheidt-Nave C, Pfeilschifter J, Barrett-Connor E: Cardiovascular death and the metabolic syndrome: role of adiposity-signaling hormones and inflammatory markers. Diabetes Care 2006, 29(6):1363-1369.
• [5]Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C: Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004, 109(3):433-438.
• [6]Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24(4):683-689.
• [7]Alexander CM, Landsman PB, Teutsch SM, Haffner SM: NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003, 52(5):1210-1214.
• [8]Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288(21):2709-2716.
• [9]Choi KM, Ryu OH, Lee KW, Kim HY, Seo JA, Kim SG, Kim NH, Choi DS, Baik SH: Serum adiponectin, interleukin-10 levels and inflammatory markers in the metabolic syndrome. Diabetes Res Clin Pract 2007, 75(2):235-240.
• [10]Jacobs M, van Greevenbroek MM, van der Kallen CJ, Ferreira I, Blaak EE, Feskens EJ, Jansen EH, Schalkwijk CG, Stehouwer CD: Low-grade inflammation can partly explain the association between the metabolic syndrome and either coronary artery disease or severity of peripheral arterial disease: the CODAM study. Eur J Clin Invest 2009, 39(6):437-444.
• [11]Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC, Taubert K, Tracy RP, Vinicor F: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107(3):499-511.
• [12]Ryu SY, Kim KS, Park J, Kang MG, Han MA: The association between circulating inflammatory markers and metabolic syndrome in Korean rural adults. J Prev Med Public Health 2008, 41(6):413-418.
• [13]Simmons RK, Alberti KG, Gale EA, Colagiuri S, Tuomilehto J, Qiao Q, Ramachandran A, Tajima N, Brajkovich Mirchov I, Ben-Nakhi A, Reaven G, Hama Sambo B, Mendis S, Roglic G: The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia 2010, 53(4):600-605.
• [14]Flegal KM, Carroll MD, Ogden CL, Johnson CL: Prevalence and trends in obesity among US adults, 1999–2000. JAMA 2002, 288(14):1723-1727.
• [15]Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287(3):356-359.
• [16]Ingelsson E, Hulthe J, Lind L: Inflammatory markers in relation to insulin resistance and the metabolic syndrome. Eur J Clin Invest 2008, 38(7):502-509.
• [17]Bayturan O, Tuzcu EM, Lavoie A, Hu T, Wolski K, Schoenhagen P, Kapadia S, Nissen SE, Nicholls SJ: The metabolic syndrome, its component risk factors, and progression of coronary atherosclerosis. Arch Intern Med 2010, 170(5):478-484.
• [18]Sundstrom J, Vallhagen E, Riserus U, Byberg L, Zethelius B, Berne C, Lind L, Ingelsson E: Risk associated with the metabolic syndrome versus the sum of its individual components. Diabetes Care 2006, 29(7):1673-1674.
• [19]Guembe MJ, Toledo E, Barba J, Martinez-Vila E, Gonzalez-Diego P, Irimia P, Diez J, Vines JJ: Association between metabolic syndrome or its components and asymptomatic cardiovascular disease in the RIVANA-study. Atherosclerosis 2010, 211(2):612-617.
• [20]Schnabel R, Larson MG, Dupuis J, Lunetta KL, Lipinska I, Meigs JB, Yin X, Rong J, Vita JA, Newton-Cheh C, Levy D, Keaney JF, Vasan RS, Mitchell GF, Benjamin EJ: Relations of inflammatory biomarkers and common genetic variants with arterial stiffness and wave reflection. Hypertension 2008, 51(6):1651-1657.
• [21]Schnabel RB, Lunetta KL, Larson MG, Dupuis J, Lipinska I, Rong J, Chen MH, Zhao Z, Yamamoto JF, Meigs JB, Nicaud V, Perret C, Zeller T, Blankenberg S, Tiret L, Keaney JF, Vasan RS, Benjamin EJ: The relation of genetic and environmental factors to systemic inflammatory biomarker concentrations. Circ Cardiovasc Genet 2009, 2(3):229-237.
• [22]Meigs JB, Wilson PW, Fox CS, Vasan RS, Nathan DM, Sullivan LM, D’Agostino RB: Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab 2006, 91(8):2906-2912.
• [23]Dawber TR, Meadors GF, Moore FE: Epidemiological approaches to heart disease: the Framingham Study. Am J Public Health Nations Health 1951, 41(3):279-281.
• [24]Pou KM, Massaro JM, Hoffmann U, Vasan RS, Maurovich-Horvat P, Larson MG, Keaney JF, Meigs JB, Lipinska I, Kathiresan S, Murabito JM, O’Donnell CJ, Benjamin EJ, Fox CS: Visceral and Subcutaneous Adipose Tissue Volumes Are Cross-Sectionally Related to Markers of Inflammation and Oxidative Stress. The Framingham Heart Study. Circulation 2007, 116(11):1234-1241.
• [25]Panagiotakos DB, Pitsavos C, Yannakoulia M, Chrysohoou C, Stefanadis C: The implication of obesity and central fat on markers of chronic inflammation: The ATTICA study. Atherosclerosis 2005, 183(2):308-315.
• [26]Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW: C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999, 19(4):972-978.
• [27]Hivert MF, Sullivan LM, Shrader P, Fox CS, Nathan DM, D’Agostino RB, Wilson PW, Benjamin EJ, Meigs JB: The association of tumor necrosis factor alpha receptor 2 and tumor necrosis factor alpha with insulin resistance and the influence of adipose tissue biomarkers in humans. Metabolism 2010, 59(4):540-546.
• [28]Straface E, Gambardella L, Canali E, Metere A, Gabrielli N, Arcieri R, Mattatelli A, Lista P, Agati L, Malorni W: P-Selection as a new gender associated biomarker in patients with metabolic syndrome. Int J Cardiol 2010, 145(3):570-571.
• [29]Gokulakrishnan K, Deepa R, Mohan V, Gross MD: Soluble P-selectin and CD40L levels in subjects with prediabetes, diabetes mellitus, and metabolic syndrome–the Chennai Urban Rural Epidemiology Study. Metabolism 2006, 55(2):237-242.